Webcast of the occasion could also be accessed by visiting Theravance.com, underneath the Traders part, Occasions and Shows. Replay of the webcast will probably be archived on the Firm’s web site for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.’s focus is to ship Medicines that Make a Distinction ® in folks’s lives. In pursuit of its function, Theravance Biopharma leverages many years of experience, which has led to the event of FDA-approved YUPELRI ® (revefenacin) inhalation resolution indicated for the upkeep therapy of sufferers with continual obstructive pulmonary illness (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in improvement for symptomatic neurogenic orthostatic hypotension (nOH) in sufferers with A number of System Atrophy (MSA), has the potential to be a primary in school remedy efficient in treating a constellation of cardinal signs in MSA sufferers. The Firm is dedicated to creating/driving shareholder worth.
For extra data, please go to www.theravance.com.
THERAVANCE BIOPHARMA ®, THERAVANCE ® and the Cross/Star brand are registered logos of the Theravance Biopharma group of corporations (within the U.S. and sure different international locations).
YUPELRI ® is a registered trademark of Mylan Specialty L.P., a Viatris firm. Emblems, commerce names or service marks of different corporations showing on this press launch are the property of their respective house owners.
Contact:
investor.relations@theravance.com
650-808-4045
